Astria Therapeutics (ATXS) Free Cash Flow: 2013-2024
Historic Free Cash Flow for Astria Therapeutics (ATXS) over the last 12 years, with Dec 2024 value amounting to -$81.5 million.
- Astria Therapeutics' Free Cash Flow fell 47.47% to -$7.8 million in Q4 2019 from the same period last year, while for Dec 2019 it was -$26.6 million, marking a year-over-year decrease of 13.23%. This contributed to the annual value of -$81.5 million for FY2024, which is 19.08% down from last year.
- Per Astria Therapeutics' latest filing, its Free Cash Flow stood at -$81.5 million for FY2024, which was down 19.08% from -$68.5 million recorded in FY2023.
- Over the past 5 years, Astria Therapeutics' Free Cash Flow peaked at -$30.2 million during FY2021, and registered a low of -$81.5 million during FY2024.
- Moreover, its 3-year median value for Free Cash Flow was -$68.5 million (2023), whereas its average is -$64.5 million.
- As far as peak fluctuations go, Astria Therapeutics' Free Cash Flow grew by 7.21% in 2021, and later tumbled by 56.95% in 2023.
- Astria Therapeutics' Free Cash Flow (Yearly) stood at -$32.5 million in 2020, then increased by 7.21% to -$30.2 million in 2021, then slumped by 44.58% to -$43.6 million in 2022, then tumbled by 56.95% to -$68.5 million in 2023, then dropped by 19.08% to -$81.5 million in 2024.